Streetbeat News

BIOVF

Swedish Orphan Biovitrum AB

https://www.sobi.com/

CEO

Guido Oelkers

Industry

Pharmaceutical Preparation Manufacturing

Open

28.30

Mkt cap

9.8B

Volume

200

High

28.62

P/E Ratio

30.77

52-wk high

32.25

Low

28.30

Div yield

N/A

52-wk low

22.87

Merck's investigational monoclonal antibody, clesrovimab, shows promising results in reducing RSV infections in infants, with a 60.4% effectiveness in a Phase 2b/3 trial. The treatment also significantly reduces hospitalizations and severe infections. Interim results from a Phase 3 trial indicate a comparable safety profile to palivizumab.

Portfolio Pulse from Vandana Singh

October 18, 2024 | 2:39 pm

Apellis Pharmaceuticals and Swedish Orphan Biovitrum released positive Phase 3 study results for pegcetacoplan in treating rare kidney diseases. The study met its primary endpoint, showing a significant reduction in proteinuria. Both companies plan to submit marketing applications in 2025.

Portfolio Pulse from Vandana Singh

August 08, 2024 | 4:53 pm

Healthcare providers are facing challenges in offering Pfizer's Abrysvo and Sanofi's Beyfortus, treatments for respiratory syncytial virus (RSV) in infants, due to insurance coverage issues and high costs. RSV is a significant threat to newborns, seniors, and adults with chronic conditions. The only previous preventative measure was Swedish Orphan Biovitrum's Synagis, costing about $1,000 per dose. Abrysvo and Beyfortus reduce the risk of severe disease or hospitalization by over 50%.

Portfolio Pulse from Vandana Singh

October 16, 2023 | 4:16 pm

Sanofi and Sobi announced positive results from the Phase 3 XTEND-Kids study of ALTUVIIIO, a first-in-class, high-sustained factor VIII replacement therapy for children with severe hemophilia A. The study met its primary endpoint with no inhibitor development to factor VIII detected and key secondary endpoints.

Portfolio Pulse from Charles Gross

June 26, 2023 | 12:19 am

The FDA's Antimicrobial Drugs Advisory Committee has unanimously voted in favor of AstraZeneca and Sanofi's nirsevimab for preventing respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants. The FDA accepted the marketing application for nirsevimab in 2022, and it could be available in the US before the 2023-2024 RSV season.

Portfolio Pulse from Vandana Singh

June 09, 2023 | 12:07 pm

Apellis Pharmaceuticals' Phase 2 MERIDIAN study for amyotrophic lateral sclerosis (ALS) failed to meet its primary and key secondary endpoints. As a result, Apellis and Swedish Orphan Biovitrum plan to discontinue the development of systemic pegcetacoplan for ALS.

Portfolio Pulse from Vandana Singh

May 25, 2023 | 5:14 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.